BRPI0907382B8 - antagonista de receptor de opioide seletivo capa, seu uso e composição farmacêutica que o compreende - Google Patents

antagonista de receptor de opioide seletivo capa, seu uso e composição farmacêutica que o compreende

Info

Publication number
BRPI0907382B8
BRPI0907382B8 BRPI0907382A BRPI0907382A BRPI0907382B8 BR PI0907382 B8 BRPI0907382 B8 BR PI0907382B8 BR PI0907382 A BRPI0907382 A BR PI0907382A BR PI0907382 A BRPI0907382 A BR PI0907382A BR PI0907382 B8 BRPI0907382 B8 BR PI0907382B8
Authority
BR
Brazil
Prior art keywords
receptor antagonist
opioid receptor
pharmaceutical composition
kappa
selective opioid
Prior art date
Application number
BRPI0907382A
Other languages
English (en)
Inventor
Howard Mitch Charles
Pedregal-Tercero Concepcion
Lee Mckinzie David
Diaz Buezo Nuria
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0907382A2 publication Critical patent/BRPI0907382A2/pt
Publication of BRPI0907382B1 publication Critical patent/BRPI0907382B1/pt
Publication of BRPI0907382B8 publication Critical patent/BRPI0907382B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

antagonista de receptor de opioide seletivo capa. a presente invenção refere-se a um antagonista de receptor de opioide capa seletivo tendo a fórmula (i) útil para tratamento de distúrbio de retirada e ansiedade de uso de etanol, e/ou depressão, ou esquizofrenia como condições co-mórbidas independentes.
BRPI0907382A 2008-01-22 2009-01-13 antagonista de receptor de opioide seletivo capa, seu uso e composição farmacêutica que o compreende BRPI0907382B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08380012.8 2008-01-22
EP08380012 2008-01-22
US3912108P 2008-03-25 2008-03-25
US61/039,121 2008-03-25
PCT/US2009/030811 WO2009094260A1 (en) 2008-01-22 2009-01-13 Kappa selective opioid receptor antagonist

Publications (3)

Publication Number Publication Date
BRPI0907382A2 BRPI0907382A2 (pt) 2015-07-21
BRPI0907382B1 BRPI0907382B1 (pt) 2020-03-10
BRPI0907382B8 true BRPI0907382B8 (pt) 2021-05-25

Family

ID=40876972

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907382A BRPI0907382B8 (pt) 2008-01-22 2009-01-13 antagonista de receptor de opioide seletivo capa, seu uso e composição farmacêutica que o compreende

Country Status (32)

Country Link
US (2) US7709522B2 (pt)
EP (1) EP2252581B1 (pt)
JP (1) JP5345637B2 (pt)
KR (1) KR101172170B1 (pt)
CN (1) CN101925576B (pt)
AR (1) AR070158A1 (pt)
AU (1) AU2009206653B2 (pt)
BR (1) BRPI0907382B8 (pt)
CA (1) CA2713025C (pt)
CO (1) CO6290644A2 (pt)
CY (1) CY1113071T1 (pt)
DK (1) DK2252581T3 (pt)
DO (1) DOP2010000222A (pt)
EA (1) EA017484B1 (pt)
EC (1) ECSP10010365A (pt)
ES (1) ES2388708T3 (pt)
HR (1) HRP20120558T1 (pt)
IL (1) IL206038A (pt)
JO (1) JO2797B1 (pt)
MA (1) MA32751B1 (pt)
MX (1) MX2010007849A (pt)
MY (1) MY163014A (pt)
NZ (1) NZ586225A (pt)
PE (1) PE20091317A1 (pt)
PL (1) PL2252581T3 (pt)
PT (1) PT2252581E (pt)
SI (1) SI2252581T1 (pt)
TN (1) TN2010000306A1 (pt)
TW (1) TWI422369B (pt)
UA (1) UA100715C2 (pt)
WO (1) WO2009094260A1 (pt)
ZA (1) ZA201003908B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5345637B2 (ja) * 2008-01-22 2013-11-20 イーライ リリー アンド カンパニー κ選択的オピオイド受容体アンタゴニスト
TW200936591A (en) * 2008-01-22 2009-09-01 Takeda Pharmaceutical Tricyclic compounds and use thereof
EP2757881A4 (en) * 2011-09-15 2014-11-12 Univ Kansas KAPPA OPIATE RECEPTOR EFFECTORS AND USES THEREOF
WO2013042054A1 (en) 2011-09-19 2013-03-28 Carmel - Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
ES2631607T3 (es) 2011-12-09 2017-09-01 Research Triangle Institute, International 4-Arilpiperazinas 1-sustituidas como antagonistas del receptor opioide kappa
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US9283196B1 (en) 2013-01-30 2016-03-15 MediSynergics, LLC Cycloalkyl-diamines for CNS disorders
ES2770978T3 (es) * 2013-05-24 2020-07-06 Alkermes Pharma Ireland Ltd Análogos de morfanos y morfinanos y métodos de uso
US10316021B2 (en) * 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
AU2018234931B2 (en) 2017-03-17 2022-05-26 Blackthorn Therapeutics, Inc. Kappa opioid receptor antagonists and products and methods related thereto
JP6480616B1 (ja) 2018-02-08 2019-03-13 有限会社 ディオン光学技研 照準スコープ
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN114195693A (zh) * 2020-09-17 2022-03-18 广东东阳光药业有限公司 一种酰胺化合物的晶型及其制备方法
CN114591211B (zh) * 2020-12-04 2025-10-21 广东东阳光药业股份有限公司 一种酰胺化合物的共晶及其制备方法
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
PH12023552963A1 (en) 2021-05-04 2024-03-11 Janssen Pharmaceuticals Inc Compositions and methods for the treatment of depression
KR20240132501A (ko) * 2022-01-10 2024-09-03 얀센 파마슈티칼즈, 인코포레이티드 우울증 치료를 위한 조성물 및 방법
MX2024008618A (es) * 2022-01-10 2024-09-25 Janssen Pharmaceuticals Inc Composiciones y métodos para el tratamiento de la depresión.
WO2023170554A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
AU2023231493A1 (en) * 2022-03-07 2024-10-24 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant
WO2023170550A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Polymorph forms of aticaprant for use in treating major depressive disorder
JP7176142B1 (ja) 2022-03-09 2022-11-21 直迪 清瀬 各アルコール飲用者において飲用し得るアルコール飲料の種類に対応する飲用量の上限値に関する情報を提供するシステム

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457208A (en) * 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
TR200103237T2 (tr) * 1999-05-12 2002-04-22 F. Hoffmann-La Roche Ag İmidazodiazepin türevi
US20020052365A1 (en) * 2000-10-05 2002-05-02 Mohler Hanns Selective anxiolytic therapeutic agents
JP2004518654A (ja) * 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
DE60319812T2 (de) * 2002-03-28 2009-04-23 Wisys Technology Foundation, Inc., Madison Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen
KR101025633B1 (ko) * 2002-09-19 2011-03-30 일라이 릴리 앤드 캄파니 오피오이드 수용체 안타고니스트로서의 디아릴 에테르
ATE406360T1 (de) * 2003-03-07 2008-09-15 Lilly Co Eli Antagonisten der opioidrezeptoren
EP1613597B1 (en) * 2003-03-07 2007-11-07 Eli Lilly and Company 6-substituted nicotinamide derivatives as opioid receptor antagonists
CA2549009A1 (en) * 2003-12-12 2005-07-07 Eli Lilly And Company Opioid receptor antagonists
ES2390459T3 (es) * 2003-12-22 2012-11-13 Eli Lilly And Company Antagonistas de receptores de opioides
ATE399164T1 (de) * 2004-03-12 2008-07-15 Lilly Co Eli Antagonisten des opioidrezeptors
EP1729759A4 (en) * 2004-03-12 2008-04-02 Mclean Hospital Corp SALVINORINE DERIVATIVES AND ITS USES
DE602005022572D1 (de) * 2004-03-12 2010-09-09 Lilly Co Eli Antagonisten des opioidrezeptors
DE602005012380D1 (de) * 2004-03-15 2009-03-05 Lilly Co Eli 4-(5-(aminomethyl)-indol-1-ylmethyl)benzamidderivate und verwandte verbindungen als opioidrezeptorantagonisten zur behandlung von fettleibigkeit
EP1735268B1 (en) * 2004-03-15 2012-02-15 Eli Lilly And Company Opioid receptor antagonists
WO2007067714A2 (en) * 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
JP5128578B2 (ja) 2006-04-04 2013-01-23 エモディス ゲーエムベーハー 解離性障害の治療のためのκ−オピオイド受容体アンタゴニスト含有組成物の利用
EP2049481A2 (en) 2006-08-09 2009-04-22 SmithKline Beecham Corporation Novel compounds as antagonists or inverse agonists for opioid receptors
EP2054383A2 (en) 2006-08-09 2009-05-06 SmithKline Beecham Corporation Novel compounds as antagonists or inverse agonists at opioid receptors
KR20090051778A (ko) 2006-09-08 2009-05-22 화이자 프로덕츠 인코포레이티드 다이아릴 에터 유도체 및 이의 용도
JP5345637B2 (ja) * 2008-01-22 2013-11-20 イーライ リリー アンド カンパニー κ選択的オピオイド受容体アンタゴニスト

Also Published As

Publication number Publication date
BRPI0907382B1 (pt) 2020-03-10
ES2388708T3 (es) 2012-10-17
US8173695B2 (en) 2012-05-08
IL206038A (en) 2013-11-28
ZA201003908B (en) 2011-11-30
TW200936129A (en) 2009-09-01
US7709522B2 (en) 2010-05-04
EA201070877A1 (ru) 2010-12-30
US20090186873A1 (en) 2009-07-23
CY1113071T1 (el) 2016-04-13
KR20100095639A (ko) 2010-08-31
JP2011524850A (ja) 2011-09-08
TN2010000306A1 (en) 2011-11-11
NZ586225A (en) 2012-05-25
PL2252581T3 (pl) 2012-10-31
JP5345637B2 (ja) 2013-11-20
EA017484B1 (ru) 2012-12-28
CA2713025A1 (en) 2009-07-30
AR070158A1 (es) 2010-03-17
AU2009206653A1 (en) 2009-07-30
DOP2010000222A (es) 2015-11-15
WO2009094260A1 (en) 2009-07-30
HK1146822A1 (en) 2011-07-15
ECSP10010365A (es) 2010-08-31
MA32751B1 (fr) 2011-11-01
CA2713025C (en) 2012-12-04
SI2252581T1 (sl) 2012-09-28
IL206038A0 (en) 2010-11-30
KR101172170B1 (ko) 2012-08-07
UA100715C2 (ru) 2013-01-25
JO2797B1 (en) 2014-03-15
TWI422369B (zh) 2014-01-11
DK2252581T3 (da) 2012-07-16
EP2252581B1 (en) 2012-06-20
CN101925576A (zh) 2010-12-22
US20100197669A1 (en) 2010-08-05
AU2009206653B2 (en) 2013-07-18
CO6290644A2 (es) 2011-06-20
EP2252581A1 (en) 2010-11-24
MY163014A (en) 2017-07-31
PE20091317A1 (es) 2009-09-03
PT2252581E (pt) 2012-08-31
HRP20120558T1 (hr) 2012-10-31
BRPI0907382A2 (pt) 2015-07-21
CN101925576B (zh) 2013-02-06
MX2010007849A (es) 2010-08-09

Similar Documents

Publication Publication Date Title
BRPI0907382B8 (pt) antagonista de receptor de opioide seletivo capa, seu uso e composição farmacêutica que o compreende
NI201000036A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3
NI201000035A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
ATE469895T1 (de) Cgrp-rezeptorantagonisten
UY33379A (es) Compuestos de morfolina
CL2009000171A1 (es) Compuestos derivados de 1-oxa-3-azaespiro, antagonistas del receptor y5 de neuropeptido y (npy); composicion farmaceutica que comprende dicho compuesto; y uso para el tratamiento de trastornos de la alimentacion, trastornos de la bebida, obesidad y depresion.
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
BR122016004010B8 (pt) forma farmacêutica oral sólida de liberação prolongada
GT200800251A (es) Nitrilos espirociclicos como inhibidores de proteasa
CL2007002316A1 (es) Compuestos derivados de pirimidina, inhibidores de pi3k; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades proliferativas como cancer.
CL2009000873A1 (es) Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b
CL2008002041A1 (es) Compuestos derivados de piperidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar ansiedad.
CR20110100A (es) Nuevos derivados de sulfamida sustituida
BRPI0919231A2 (pt) agonista de receptor de neuropeptídeo-2, composição farmacêutica que o compreende, seu uso e método para o tratamento ou profilaxia de enfermidades
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
BRPI0910780A2 (pt) uso de antagonistas de opióides para o tratamento da retenção urinária
BRPI0907230A2 (pt) composto, prodroga do composto, fármaco, método para tratar ou prevenir uma doença associada com as funções de um receptor de crf, e, uso do composto
CU20090085A7 (es) Antagonistas del receptor de progesterona
CO6260091A2 (es) Derivados de iminopiridina y su uso
PA8790101A1 (es) Derivados de aminoalquilazol como antagonistas de histamina-3
UY32521A (es) Combinación para emplear en el tratamiento de enfermedades respiratorias
PA8814801A1 (es) Triazolopiridazinas como inhibidores de par1, su preparación y su uso como medicamentos
CL2008001162A1 (es) Compuestos derivados de piperidina, antagonista del receptor de taquiquinina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto para el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal, una enfermedad del sistema nervioso central.
AR058127A1 (es) Derivados de piperidina antagonistas de cgrp, procedimientos para su preparacion asi como su uso como medicamentos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/03/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/01/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF